Giant Biogene Reshapes Corporate Secretariat With New Joint Company Secretary

Giant Biogene Holding Co. Ltd. ( (HK:2367) ) has provided an update.

Giant Biogene Holding Co. Ltd. announced that joint company secretary and authorised representative Ms. Yuen Wing Yan, Winnie has resigned from her roles, including as the company’s process agent in Hong Kong, effective 8 April 2026, with no disagreements reported with the board. She will be succeeded by Ms. Au-Yeung Nelly, a senior manager at Tricor Services Limited with over a decade of corporate secretarial experience, who will serve as joint company secretary, authorised representative and process agent alongside continuing joint company secretary Ms. Yan Yubo, reinforcing the company’s compliance and governance framework.

The board highlighted Ms. Au-Yeung’s professional qualifications as a Chartered Secretary and Chartered Governance Professional, and her existing roles with other Hong Kong-listed companies. By appointing an experienced governance specialist while retaining Ms. Yan in her joint position, Giant Biogene aims to ensure continuity in listing rule compliance and strengthen its corporate governance structure for shareholders and other stakeholders.

The most recent analyst rating on (HK:2367) stock is a Buy with a HK$38.70 price target. To see the full list of analyst forecasts on Giant Biogene Holding Co. Ltd. stock, see the HK:2367 Stock Forecast page.

More about Giant Biogene Holding Co. Ltd.

Giant Biogene Holding Co. Ltd. is a Cayman Islands–incorporated company listed on the Hong Kong Stock Exchange. The company operates within the biopharmaceutical and biotechnology sector, focusing on research-driven products and related healthcare applications for the mainland China market and international investors.

Average Trading Volume: 5,340,486

Technical Sentiment Signal: Sell

Current Market Cap: HK$29.97B

Find detailed analytics on 2367 stock on TipRanks’ Stock Analysis page.